Beam Therapeutics (BEAM) Revenue (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Revenue data on file, last reported at $31.7 million in Q1 2026.

• Revenue for Q1 2026 came in at $31.7 million, up 324.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $164.0 million (up 157.97% YoY), and the FY2025 annual result was $139.7 million, up 120.01% from the prior year.
• Revenue eased to $31.7 million in Q1 2026 per BEAM's latest filing, from $114.1 million in the prior quarter.
• Over five years, Revenue peaked at $316.2 million in Q4 2023 and troughed at $7.4 million in Q1 2024.
• A 5-year average of $39.6 million and a median of $16.7 million in 2022 frame the typical range for Revenue.
• The sharpest annual moves came in 2022 and 2024: Revenue soared 277433.33% in 2022, then slumped 90.49% in 2024.
• A 5-year view of Revenue shows it stood at $20.0 million in 2022, then jumped by 1478.04% to $316.2 million in 2023, then tumbled by 90.49% to $30.1 million in 2024, then surged by 279.52% to $114.1 million in 2025, then tumbled by 72.19% to $31.7 million in 2026.
• Business Quant data shows BEAM's Revenue at $31.7 million in Q1 2026, $114.1 million in Q4 2025, and $9.7 million in Q3 2025.